Please login to the form below

Not currently logged in
Email:
Password:

amyloid plaque

This page shows the latest amyloid plaque news and features for those working in and with pharma, biotech and healthcare.

Takeda and Zinfandel abandon Alzheimer’s drug

Takeda and Zinfandel abandon Alzheimer’s drug

Meanwhile, other diabetes drugs have also been tested for activity in AD, including Novo Nordisk's Victoza (liraglutide) which seemed to reduce amyloid plaque formation but had no effect on cognitive

Latest news

  • Biogen says trial extension data keep Alzheimer's drug on track Biogen says trial extension data keep Alzheimer's drug on track

    In both cases, the benefits on CDR-SB and MMSE extended into the second and third years and tracked significant decreases in amyloid plaque in the brains of patients. ... the negative trial had "minimal to no negative read across to the amyloid hypothesis

  • Novartis launches Alzheimer’s prevention study Novartis launches Alzheimer’s prevention study

    Like many other investigational Alzheimer's treatments solanezumab and gantenerumab are developed to work by targeting the build up of amyloid plaque in the brain. ... It is intended to trigger the body's immune system to fight the onset of amyloid.

  • Eisai and Biogen partner on Alzheimer’s Eisai and Biogen partner on Alzheimer’s

    As part of the collaboration, the companies will jointly develop Eisai's two drug candidates E2609 and BAN2401, both of which are designed to target build-ups of amyloid plaque in ... E2609 is a BACE inhibito r, a relatively new class of dementia

  • Lilly acquires Alzheimer’s diagnostics from Siemens Lilly acquires Alzheimer’s diagnostics from Siemens

    These tau tangles are thought to block the transport of molecules throughout the cell – leading to neurodegeneration – and alongside amyloid plaque, are one of two known hallmarks for Alzheimer's disease. ... Pharma interest in tau-targeted medicines

  • Lilly gets go-ahead for Alzheimer’s diagnostic in EU Lilly gets go-ahead for Alzheimer’s diagnostic in EU

    being able to see whether amyloid plaques are present in the brain will help the accuracy of diagnosis. ... Amyvid is the first and only diagnostic tool approved for use in the European Union that can show the presence or absence of beta-amyloid neuritic

More from news
Approximately 2 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Interview: Jan Lundberg, Eli Lilly Interview: Jan Lundberg, Eli Lilly

    also an oral agent to implant the amyloid pathway that is planned to go into phase II this year. “ ... We also have an upcoming diagnostic opportunity in Alzheimer's: an imaging agent that can be used to detect amyloid plaque in the living human brain,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
StratX

StratX creates experiential learning programs instilled with emotion and competitive spirit, leading to lasting on-the-job change. Our memorable approach develops...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics